Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study

Blood

Volumn 99, Issue 4, 2002, Pages 1150-1158

  Luger, Selina M ^a,b,c   O'Brien, Stephen G ^a,b,c   Ratajczak, Janina ^a,b,c   Ratajczak, Mariusz Z ^a,b,c   Mick, Rosemarie ^a,b,c   Stadtmauer, Edward A ^a,b,c   Nowell, Peter C ^a,b,c   Goldman, John M ^a,b,c   Gewirtz, Alan M ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE;

ADULT; ARTICLE; AUTOGRAFT; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG DELIVERY SYSTEM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE TARGETING; HUMAN; LEUKEMIA REMISSION; MALE; METAPHASE; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037082474     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.4.1150     Document Type: Article

References (96)

1. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
2. Gene therapy: Designer promoters for tumour targeting
3. Cancer gene therapy: Hard lessons and new courses
4. Nucleic acid therapeutics: State of the art and future prospects
5. Nucleic acid enzymes: Playing with a fuller deck
6. Gene therapy for chronic myelogenous leukemia
7. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes)
8. Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics
9. Oligonucleotide therapeutics: A step forward
10. Role of the KIT protooncogene in normal and malignant human hematopoiesis
11. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
12. A reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis
13. Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line
14. A functional analysis of protooncogene Vav's role in adult human hematopoiesis
15. Effect of hepatocyte growth factor on early human haemopoietic cell development
16. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PIGF) in regulating human haemopoietic cell growth
17. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro
18. G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb
19. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging
20. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides
21. Myb targeted therapeutics for the treatment of human malignancies
22. The c-Myb oncoprotein
23. The myb gene family in cell growth, differentiation and apoptosis
24. Viral myb oncogene encodes a sequence-specific DNA-binding activity
25. c-Myb transactivates the human cyclin A1 promoter and induces cyclin A1 gene expression
26. Cyclin A1 directly interacts with B-myb and cyclin A1/cdk2 phosphorylate B-myb at functionally important serine and threonine residues: Tissue-specific regulation of B-myb function
27. The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene
28. Regulation of the expression of the hematopoietic stem cell antigen CD34: Role of c-myb
29. Myeloblastin is an Myb target gene: Mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid
30. A functional c-myb gene is required for normal murine fetal hepatic hematopolesis
31. The homeobox gene GBX2, a target of the myb oncogene, mediates autocrine growth and monocyte differentiation
32. Reassessing the role of C-MYB in tumorigenesis
33. Myb binding proteins: Regulators and cohorts in transformation
34. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides
35. Oligodeoxynucleotide-based therapeutics for human leukemias
36. Myb and ets proteins are candidate regulators of c-kit expression in human hematopoietic cells
37. Analysis of pleiotropism at the dominant white-spotting (W) locus of the house mouse: A description of ten new W alleles
38. Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: Basis for radiosensitivity of white spotting and steel mutant mice
39. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
40. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells
41. Defective c-myc and c-myb RNA turnover in acute myeloid leukemia cells
42. Identification of protein instability determinants in the carboxy-terminal region of c-Myb removed as a result of retroviral integration in murine monocytic leukemias
43. Interaction of the v- and c-Myb proteins with regulatory sequences of the human c-myc gene
44. Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis
45. Dominant negative MYC blocks transformation by ABL oncogenes
46. The role of c-Myc protooncogene in chronic myelogenous leukemia
47. Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells
48. CD34+, kit+, rhodamine 123(low) phenotype identifies a marrow cell population highly enriched for human hematopoietic stem cells
49. Biologic and therapeutic significance of MYB expression in human melanoma
50. Autografting in chronic myeloid leukemia with cultured marrow: Update of the Vancouver Study
51. Differences between normal and CML stem cells: Potential targets for clinical exploitation
52. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia
53. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation
54. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide
55. Does antisense exist?
56. Antisense technology and prospects for therapy of viral infections and cancer
57. RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts
58. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
59. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
60. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
61. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
62. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer
63. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
64. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects
65. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects
66. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
67. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise
68. Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia
69. Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse
70. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses
71. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs
72. Molecular and cellular characterization of baboon C-Raf as a target for antiproliferative effects of antisense oligonucleotides
73. Dislodgment and accelerated degradation of Ras
74. Kinetic selectivity of complementary nucleic acids: Bcr-abl-directed antisense RNA and ribozymes
75. Rapid determination and quantitation of the accessibility to native RNAs by antisense oligodeoxynucleotides in murine cell extracts
76. Real time detection of DNA.RNA hybridization in living cells
77. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase
78. BCR-ABL BCR proteins: Biochemical characterization and localization
79. Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells
80. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia
81. Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis
82. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines
83. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320)
84. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific
85. Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study
86. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups
87. Autologous peripheral blood haematopoietic stem cell transplantation for chronic myelogenous leukaemia
88. Chronic myeloid leukemia
89. Hematopoietic stem cell transplantation in chronic myeloid leukemia
90. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
91. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
92. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: An EBMT retrospective analysis
93. Autologous stem cell transplantation in acute myelocytic leukemia
94. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
95. Autologous stem cell transplantation for anaplastic large-cell lymphomas: Results of a prospective trial
96. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)